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Background: Reasons for the variation in response of deep vein thrombosis (DVT) to anticoagulation treatment are
not known. Some patients develop complications such as post-thrombotic syndrome or recurrent DVT but others
make a full recovery. The aim of the study is to identify the level of variation in response to anticoagulation
treatment and provide more precise and quantitative disease characterisation in response to treatment.
Methods: A prospective observational study using duplex ultrasound to examine changes in thrombus
characterisation, evolution and resolution over a 2 year period in patients with a confirmed DVT. Logistic regression
analysis will be used to seek associations between characteristics present at baseline and the outcomes of DVT
resolution, recurrence and the development of post-thrombotic syndrome (PTS).
Discussion: This research into the response to treatment of lower limb DVT and predictive factors for DVT
resolution, recurrence and PTS could inform a more tailored approach to anticoagulation therapy for the future
management of DVT.
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Deep vein thrombosis (DVT) is a blood clot or
thrombus in one of the deep veins of the body. It is a
common clinical condition which usually affects the
deep veins of the lower limbs and abdomen. It is known
to have a number of well-recognised, potentially life-
threatening complications including pulmonary embol-
ism as well as chronic long-term sequelae related to the
lower limb itself, a condition known as post thrombotic
syndrome (PTS) [1].
Research evidence to date suggests that there is vari-
ability in the response to treatment in terms of throm-
bosis resolution and residual venous function. Some
thromboses may resolve before the course of anticoagu-
lation treatment is completed and some may not be re-
solved upon completion of the treatment cycle. Some
patients may recover fully from having had a DVT and* Correspondence: michelle.bonfield@uhbristol.nhs.uk
1Vascular Studies Unit, University Hospitals Bristol NHS Foundation Trust,
Bristol, UK
2University of the West of England, Bristol, UK
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeothers may be left with on-going problems associated
with chronic venous hypertension. However, clinical
ultrasound imaging is not routinely used on completion
of the course of anticoagulation treatment to establish
the status of the thrombosis or residual venous function.
The length of treatment or the decision to stop or con-
tinue treatment is therefore not informed by either the
degree of resolution of the DVT (i.e. the presence of re-
sidual thrombus) or the residual venous function. There
is debate whether prolonged anticoagulation could bene-
fit certain patient groups in terms of reducing the risk of
recurrence and the development of PTS.
Not every patient that has a DVT will develop a recur-
rent DVT or PTS but there is a lack of research evidence
to indicate which patients are at risk. Recurrent, ipsilat-
eral DVT is the best established risk factor for PTS,
increasing the risk as much as six-fold compared to pa-
tients without recurrence [2–5]. These studies however
are 17–20 years old and are therefore based on old ultra-
sound technology. There is also no agreement regarding
the impact of other factors such as DVT location orle is distributed under the terms of the Creative Commons Attribution 4.0
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and the presence of residual thrombus, nor patient char-
acteristics such as age, gender or body mass index on
the risk of developing PTS.
New technological developments in the field of ultra-
sound allow for much improved visualisation of smaller
vessel DVT and residual thrombus so there is justifica-
tion for a new study in this field using the latest ultra-
sound technology. The research undertaken into the
response to treatment of lower limb DVT and predictive
factors for recurrence and PTS could inform a more tai-
lored approach to anti-coagulation therapy for the future




a) Record thrombus morphology, evolution and reso-
lution in a DVT patient population to identify the level
of variation in response to anticoagulation treatment
and provide more precise and quantitative disease char-
acterisation in response to treatment.
b) To detect associations between characteristics
present at baseline and outcomes identified during
follow-up.
Study design
A single centre prospective observational study.
Study population
Patients referred to the rapid access Thrombosis Clinic
at University Hospitals Bristol (UHBristol) for suspected
DVT and subsequently diagnosed with a DVT on ultra-
sound. Patients are referred to the Thrombosis Clinic at
UHBristol from both primary care and from within the
hospital. The study population mainly comprises outpa-
tients but patients diagnosed with a DVT through this
service whilst an inpatient may be included in the study
providing they meet the inclusion criteria.
Inclusion criteria
Symptomatic adult patients aged between 18 and
85 years, diagnosed with a confirmed lower limb DVT
on ultrasound. The diagnosis of lower limb DVT is
made where partial or occlusive thrombus is present in
any of the deep veins by either direct ultrasonic visualisa-
tion of intraluminal thrombus, lack of complete compress-
ibility or absence of flow following distal compression.
Exclusion criteria
Patients with mobility issues that prevent them return-
ing for follow-up appointments or are unable to lie
down or transfer to an examination couch, patients that
are pregnant, those with active cancer and intra-venousdrug users are excluded from the study. Patients were
asked if they are participating in any other research
when approached to consider participation in the study;
if the other research study had the potential to confound
this study, subjects were not recruited.
Primary outcomes
The prospective observational study uses duplex ultra-
sound to examine changes in thrombus characterisation,
evolution and resolution over time in patients with a
confirmed DVT on ultrasound. The primary outcomes
of the study are DVT resolution, recurrence and the
development of PTS.
Sample size calculation
The sample size calculation was based on the work of
Peduzzi et al. [6] and reported by van Belle [7] as a
guideline for the minimum number of subjects required
to quantify regression coefficients with reasonable preci-
sion in an epidemiological study of this kind. The vari-
ables for examination will be identified from the
research data as described previously so their precise
number and their relationship with the primary outcome
is not yet determined. Based on a calculation where p is
the smallest of the proportions of negative or positive
cases of PTS in the population and k the number of co-
variates, the minimum number of subjects to include
can be calculated as: N = 10 k / p. Using research evi-
dence that suggests that at least 20 % of patients with
symptomatic DVT will develop PTS within 2 years
despite ‘adequate’ treatment of DVT and assuming
three covariates the minimum number of patients
required would be 150.
Study methods
To provide denominator data for the study, records have
been kept of all patients that were referred to the
Thrombosis Clinic service, UHBristol for ultrasound as-
sessment for lower limb DVT during the recruitment
period, including those with a negative diagnosis. Details
have been kept of the recruitment process including the
reasons for exclusion and where provided, reasons for
patients’ refusal to participate.
On ultrasound diagnosis of a lower limb DVT, each
potential participant was assessed for eligibility and, if
appropriate, offered an invitation letter and patient in-
formation leaflet. If interested in principle, the patient
was asked to provide a contact telephone number and
convenient contact time. The chief investigator would
then contact the potential participant by telephone after
24–48 h to ask them if they wished to participate in the
study and to answer any questions they may have. If they
agreed, a first follow-up appointment was scheduled for
7 days post diagnosis. Written consent to participate in
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follow up visit by the chief investigator in accordance
with Good Clinical Practice. Each participant will remain
in the study for 2 years post diagnosis.
Complete diagnostic ultrasound assessment of the
proximal and distal lower limb veins using a combin-
ation of colour and spectral Doppler and compression
ultrasound is undertaken on initial presentation. The
diagnostic ultrasound is undertaken by Clinical Vascular
Scientists from the Vascular Studies Unit, UHBristol
who are trained locally under the standards of the Na-
tional School of Healthcare Science NHS Scientist
Training Program. The unit performs between 2000 and
2400 diagnostic ultrasound assessments for DVT annu-
ally and has a detection rate of 20–24 %. The following
details are recorded: thrombosis location and extent, if
the thrombosis is occlusive or partially occlusive and if
adherence to the vessel wall is complete or partial. Any
relevant clinical history is recorded at initial presentation
including the nature and duration of any clinical
symptoms.
The presence of any pre-existing medical conditions is
recorded at each participant’s first follow-up visit, as well
as the baseline details for gender, age and body mass
index. Details are recorded of all prescription medica-
tions currently being taken by each participant and of
any non-prescription medications/vitamins/supplements
being taken regularly. Any changes in medical history,
prescription medicines and body mass index are re-
corded at each study visit.
The follow-up schedule comprises six visits for those
participants with a first episode of DVT in the limb con-
cerned at the following intervals: 1 week, 1 month,
3 months, 6 months, 1 year and 2 years. Participants
with a history of previous ipsilateral DVT will undergo
three follow up visits at 1 week, 6 months and 2 years.
At each visit participants undergo full compression
ultrasound assessment of the complete lower limb ven-
ous tree from the level of the inguinal ligament to the
ankle (common femoral vein, popliteal vein, peroneal
veins, posterior tibial veins, anterior tibial veins, soleal
veins, gastrocnemius veins, greater saphenous vein and
short saphenous vein) to identify the presence or ab-
sence of residual or new DVT or superficial thrombo-
phlebitis in each venous segment. The ultrasound
assessment is undertaken by the chief investigator who
is a Health and Care Professions Council (HCPC) regis-
tered Clinical Vascular Scientist and is professionally
accredited by the Society for Vascular Technology of
Great Britain and Ireland (SVTGBI). The presence of
thrombus is recorded as occlusive or non-occlusive and
details of recanalization patterns are recorded in each
segment. If the original diagnostic scan identifies the
presence of thrombus in the iliac veins then theabdominal venous system is also scanned in full at each
follow-up visit. In all cases, if flow in the common fem-
oral vein on spectral Doppler ultrasound is not phasic
with respiration, a full assessment of the external iliac
vein, common iliac vein and inferior vena cava is under-
taken using colour and spectral Doppler ultrasound.
Fifteen venous segments are assigned a thrombus
score at each visit: inferior vena cava, common iliac vein,
external iliac vein, common femoral vein, profunda
femoris vein, proximal femoral vein, distal femoral vein,
popliteal vein, peroneal veins, posterior tibial veins, an-
terior tibial veins, soleal veins, gastrocnemius veins,
greater saphenous vein and short saphenous vein.
The thrombus load score is adapted from the updated
reporting standards in venous disease from the Ad Hoc
Committee on Reporting Standards of the Joint Council
of the Society for Vascular Surgery and the North
American Chapter of the International Society for
Cardiovascular Surgery [8] and a modified version of
Haenan’s clot score as used by van Rij et al. [9].
Each venous segment is scored as follows:
0 = patent
1 = subsegmental, non-occlusive thrombus
2 = subsegmental, occlusive thrombus
3 = occlusive thrombus throughout segment
A duplex ultrasound assessment for the competency
of the deep and superficial veins is undertaken by the
chief investigator at each visit. Pulsed and colour Dop-
pler is utilised to assess flow characteristics within the
veins including phasicity, spontaneity and direction of
flow. Flow characteristics are assessed in a longitudinal
scan plane. The patient are examined standing or at a
minimum of 30° degree angle on a tilting table in order
to assess the competency of the venous valves against
gravity. Manual distal compression is applied to the calf
to augment the flow and to assess for reflux. Venous in-
competence is defined as a reflux time >0.5 s [10].
At each visit, a detailed clinical assessment is made of
the leg in which the thrombosis is/was present and the
patients’ symptoms, including pain, aching, heaviness,
itching, cramp and paraesthesia are recorded using an
interviewer-administered questionnaire. The Villalta
Scale [11] will be used to quantify the symptoms of the
burden of venous disease. The presence of oedema, tele-
angiectasias, reticular veins, varicose veins, hyperpig-
mentation, eczema, lipodermatosclerosis and ulceration
are recorded according to the Clinical, Etiological, Ana-
tomical and Pathophysiological (CEAP) classification
system for classifying venous disease severity.
Details of the anti-coagulation treatment received by
each patient in the study are collected as it is recognised
that there are several different anti-coagulation therapies
Bonfield et al. BMC Hematology  (2016) 16:24 Page 4 of 5available and that variation in anti-coagulation regimes
can occur depending on patient pathway, patient profile,
patient choice and primary care follow-up. Adequacy of
anticoagulation therapy is monitored through access to
the participants’ medical records where relevant (vitamin
K antagonists where international normalized ratio
(INR) is monitored) and compliance with taking new
oral anticoagulants (NOACs) is assessed by direct ques-
tioning at each visit. Participants’ compliance with com-
pression stocking use is also recorded at each visit as ‘no
use’, ‘occasional use’ or ‘routine use all day, every day’.
Any participant identified as having a recurrent DVT
or an existing DVT that has extended at any point dur-
ing follow-up is immediately reviewed by the rapid ac-
cess thrombosis clinic. A recurrent DVT is diagnosed as
the presence of a new thrombus either in the ipsilateral
or contralateral leg or the presence of new thrombus on
old thrombus in the same venous section as the original
thrombosis, all of which are confirmed on Duplex
ultrasound.Data analysis
International Business Machines Corporation Statistical
Product and Service Solutions (IBM SPSS) Version 20
(IBM, Armonk, New York, USA) will be used for nu-
merical operations. Initial analysis will involve running
descriptive statistics. Individual and multi-sector vein
thrombus presence and change will be analysed for pat-
terns and categories of resolution and recurrence over
the 48 month follow-up period. Frequencies will be per-
formed for each predictor in addition to the sample size
and age and sex distributions. Crude odds ratios and
their confidence limits will be calculated to describe the
strength of association between each independent vari-
able and the primary outcome variables [12]. A chi-
square test of independence will initially be performed
to highlight the categorical variables with a significant
relationship to the dependent variable for inclusion in
regression modelling. Logistic regression analysis will be
used to compute the adjusted regression coefficients and
confidence limits of variables predictive of DVT recur-
rence and PTS.
The timing of any DVT recurrence and post throm-
botic syndrome will be assessed using survival analytical
methods such as Kaplan and Meier [13], with Cox re-
gression employed to quantify covariate hazard rates.
The variance inflation factor will be used to identify
any concerns that multicollinearity poses a threat to the
regression analysis and to determine the individual im-
portance of each predictor [14]. An analysis of the basic
residual statistics of the model will be undertaken to
identify cases exerting undue influence over the parame-
ters of the model [14].Discussion
Study status
Since February 2014, 195 participants were recruited to
the study. The study closed to recruitment in January
2016 and the first participants completed 2 years of fol-
low up in February 2016. Data collection will continue
until January 2018 with results expected to be published
in late 2018.
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